Drug intelligence / Profile preview

CBDEX10

Development stage: Unknown
Lead developer: Shahid Beheshti University of Medical Sciences
Modality: Small Molecules
Administration: Sublingual

Overview

**CBDEX10** is an investigational fixed-dose, sublingual cannabinoid spray developed by Yas Daru for adjunctive treatment of type 2 diabetes mellitus. Each puff delivers 100 micrograms of cannabidiol and 10 micrograms of delta-9-tetrahydrocannabinol in a 10:1 ratio. In a randomized, double-blind, placebo-controlled phase 1 study, two puffs twice daily for eight weeks were evaluated for glycemic and lipid control; the publication reported improvements in fasting glucose, hemoglobin A1c, insulin resistance, total cholesterol, triglycerides, and LDL cholesterol versus placebo. ([brieflands.com](https://brieflands.com/journals/ijpr/articles/132647))

Brand names: CBDEX10CBDEX-10CBDEX 10
Other names: CBDEX1CBDEX-1CBDEX 1

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on CBDEX10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBDEX10.

Explore the full profile